Journal of Pharmacokinetics and Biopharmaceutics, Vol. 1, No. 6, 1973

Author Index to Volume 1

Alexander, K., 201
Änggård, E., 481
Ashley, J. J., 99, 231

Becker, C., 307
Benet, L. Z., 1, 83, 123
Bischoff, K. B., 51, 69, 465

Colaizzi, J. L., 267
Cotler, S., 201

Dedrick, R. L., 435
DeHaan, R. M., 89
del Pozo, A., 243
Dettli, L., 403
Dittert, L. W., 5, 253
Doluisio, J. T., 5, 253

Finn, C., 295
Forist, A. A., 89

Garrett, E. R., 341
Gibaldi, M., 17
Gillette, J. R., 497
Giorgi, G., 217
Graham, G., 123
Griffen, W. O., Jr., 5
Gunne, L.-M., 481

Himmelstein, K. J., 51, 69
Hinsvark, O. N., 319

Jack, M. L., 201
Jaffe, J. M., 267
Jenden, D. J., 319
Jusko, W. J., 175

Kaplan, S. A., 201

LaPiana, J. C., 253
Lehmann, B. v., 307
Levy, G., 99, 231, 541
Levy, R. H., 283

Martis, L., 283
Matin, S. B., 553
McDonald, R. H., Jr., 267
Metzler, C. M., 89
Moreno, J., 243

Perrier, D., 17, 231
Pfeffer, M., 137
Pilbrant, A., 307
Plá-Delfina, J. M., 243
Poust, R. I., 267

Riegelman, S., 1, 83, 307, 419
Rowland, M., 1, 83, 123, 419, 553

Sadee, W., 295
Schuppan, D., 307
Sedman, A. J., 23
Segal, J., 295
Segre, G., 217
Smith, R. B., 5
Smolen, V. F., 329
Steinborn, J. A., 319

Truant, A. P., 319

Vesell, E. S., 521

Wagner, J. G., 23, 103, 165, 337, 363
Weigand, W. A., 329

© 1973 Plenum Publishing Corporation, 227 West 17th Street, New York, N.Y. 10011. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise, without written permission of the publisher.

Journal of Pharmacokinetics and Biopharmaceutics, Vol. 1, No. 6, 1973

Subject Index to Volume 1

Absorption kinetics, 5, 243, 283, 363
Accumulation, 403
Allobarbital, 243
Amobarbital, 243
Amphetamine, 319, 481
Animal models, 435
Anticoagulant effect, pharmacokinetics of, 541
Antipyrine, 521
Arabinosylcytosine, 175
ARA-C, 69, 435
Area under the curve measurements, 201

Barbiturates, 243
Biliary excretion, 217, 363
Bioavailability, 3, 83, 283, 319, 329, 341, 419
Biopharmaceutics, definition, 3
Biophasic availability, 329
Biotransformation products, 201
Bishydroxycoumarin, 521
Blood flow limited absorption, 419
Body weight relationships, 435
Buccal absorption, 23

Cancer chemotherapy, 51, 69, 175, 465
Capacity-limited elimination, 283
Carbon tetrachloride intoxication, 217
Cell cycle specific drugs, 51, 175, 465
Cell kinetics, 51, 175, 465
Chloride pharmacokinetics, 435
Chromatographic partition systems, 243
Chronopharmacology, 435
Clinical medicine in pharmacokinetics, 403
Clinical metabolic profile, 341
Corticosterone, 497
Coumarin drugs, 541
Creatinine levels, 253
Cyclobarbital, 243
Cyclophosphamide, 175, 465
Cytosine arabinoside, 69, 435, 465

Deconvolution, numerical, 217
Diazoxide, 295
Dicoumarol, 541
Disposition, 3, 419
Distribution, nonlinear, 363
Dosage regimens, 253, 341
Dose-dependent kinetics, 231
Doxycycline hyclate, 267
Drug–drug interactions, 553

Erratum, 337
Ethanol, 521
N_4-Ethoxyacetylsulfamethoxazole, 201
Excretion rate plot, 267
Extraction theory, 23

First-pass effect, 419
Food effects, 5

GC–mass fragmentography, 295
Griseofulvin–phenobarbital interaction, 553

Hepatic first-pass effect, 419
Heritability, pharmacokinetic, 521
Hexobarbital, 243
p-Hydroxyamphetamine, 481

Inhibitor constants, 553
Intestinal metabolism, 419
Isotopes, use in bioavailability testing, 83

Kanamycin, 253
Kidney disease, 403
Krüger-Thiemer's dosage theory, 403

Leukemia, L1210 models, 69
Liver damage, 217

Mass fragmentography, 295
Mephobarbital, 243
Metharbital, 243
Methotrexate, 435, 465
α-Methyltyrosine, 481
Michaelis–Menten kinetics, 231, 337, 363, 553
Multiple dosing, 17

Nonlinear kinetics, 231, 283, 363

Oral absorption, 419

Partition coefficient, 23, 497
Pentobarbital, 5, 243
Perfusion-limited absorption, 419

© 1973 Plenum Publishing Corporation, 227 West 17th Street, New York, N.Y. 10011. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise, without written permission of the publisher.

Perfusion models, 435
pH, urinary, 267
Pharmacokinetics, definition, 3
Pharmacokinetic models, 341
Phenobarbital, 243
Phenobarbital–griseofulvin interaction, 553
Phentermine, 319
Phenylbutazone, 521
Phenylbutazone–warfarin interaction, 553
Plasma protein binding, 363, 497
Polygenically controlled disease states, 521
Probarbital, 243
Product inhibition, 231
Propythiouracil, 307
Protein binding, 497
Protein displacement, 553

Radioactive compounds, 83
Renal excretion, 295, 363, 403
Renal insufficiency, 253
Renal reabsorption, 23
Resin-bound drugs, 319

Salicylamide, 419
Saturation phenomena, 403
Sites of drug action, 341
Stable-isotope dilution–mass fragmentography, 295
Steady state distribution, 17
Substrate inhibition, 231
Sulfamethoxazole derivative kinetics, 201
Sulfaphenazole–tolbutamide interaction, 553
Sulfobromophthalein kinetics, 217

Tetracycline hydrochloride, 267
Thiopental, 243, 435
Tissue binding, 363, 497
Tissue distribution, 497
Tolbutamide metabolites, 553
Tolbutamide–sulfaphenazole interaction, 553
Twin studies, 521

Urinary pH, 267, 481

Vinblastine, 175
Vincristine, 175
Volumes of distribution, 17, 497

Wagner–Nelson method, 283
Warfarin, 541
Warfarin–phenylbutazone interaction, 553

JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS
Volume 1, 1973

A journal devoted to illustrating the importance of pharmacokinetic and biopharmaceutical applications in the understanding of drug action, design, therapy, and evaluation. Experimental and theoretical papers deal with: kinetics of drug disposition; clinical pharmacokinetics; time course of pharmacological response; factors affecting formation and disposition of drug metabolites; studies in drug release from dosage forms; dosage form developments and their evaluation in animals and man; bioavailability studies—*in vitro* and *in vivo* correlations; and application of computers to pharmacokinetic analysis. All papers show some correlation with data describing the time course of drug disposition or action, or both, in animals and man.

EDITOR

Sidney Riegelman
Professor of Pharmacy and Pharmaceutical Chemistry, Chairman, Department of Pharmacy, School of Pharmacy, University of California, San Francisco, California

ASSOCIATE EDITORS

Leslie Z. Benet
Associate Professor of Pharmacy and Pharmaceutical Chemistry, School of Pharmacy, University of California, San Francisco, California

Malcolm Rowland
Associate Professor of Pharmacy and Pharmaceutical Chemistry, School of Pharmacy, University of California, San Francisco, California

CONSULTING EDITORS

E. R. Garrett, University of Florida, Gainesville, Florida
T. Higuchi, University of Kansas, Lawrence, Kansas
G. Levy, State University of New York, Buffalo, New York
G. Segre, University of Siena, Siena, Italy
T. Teorell, Institute of Physiology and Medical Biophysics, Uppsala, Sweden
J. van Rossum, University of Nijmegen, Nijmegen, The Netherlands
J. G. Wagner, University of Michigan, Ann Arbor, Michigan

EDITORIAL ADVISORY BOARD

A. J. Aguiar, Pfizer, Inc., Groton, Connecticut
D. L. Azarnoff, University of Kansas Medical Center, Kansas City, Kansas
W. H. Barr, Medical College of Virginia, Richmond, Virginia
A. H. Beckett, University of London, London, England
M. Berman, National Institutes of Health, Bethesda, Maryland
K. B. Bischoff, Cornell University, Ithaca, New York
L. Dettli, Medizinische Universitätsklinik, Basel, Switzerland
H.-W. Dibbern, Pharma-Qualitätskontrolle, Frankfurt am Main, West Germany
C. T. Dollery, University of London, London, England
J. T. Doluisio, University of Texas, Austin, Texas
F. H. Dost, Universitäts-Kinderklinik, Giessen, West Germany
P. Finholt, University of Oslo, Oslo, Norway
M. Gibaldi, State University of New York, Buffalo, New York
E. Gladtke, Universitäts-Kinderklinik Köln, Köln, West Germany
L. I. Goldberg, Emory University, Atlanta, Georgia
W. I. Higuchi, University of Michigan, Ann Arbor, Michigan
J. Hirtz, Ciba-Geigy, Rueil-Malmaison, France
I. Janků, Czechoslovak Academy of Sciences, Prague, Czechoslovakia
C. M. Metzler, The Upjohn Company, Kalamazoo, Michigan
J. W. Poole, Wyeth Laboratories, Philadelphia, Pennsylvania
F. Sjöqvist, Karolinska Institutet, Stockholm, Sweden
H. Stander, Sterling-Winthrop Research Institute, Rensselaer, New York
J. Swarbrick, Sterling-Winthrop Research Institute, Rensselaer, New York

---

Published bimonthly at Winterstoke Road, Bristol 3, England, by Plenum Publishing Corporation, 227 West 17th Street, New York, N.Y. 10011. In 1973, Volume 1 (6 issues) will be published. Subscription orders should be addressed to the publisher. *Journal of Pharmacokinetics and Biopharmaceutics* is abstracted or indexed in Biological Abstracts, Chemical Abstracts, Excerpta Medica, Current Contents, and International Pharmaceutical Abstracts.

Subscription rate:

Volume 1, 1973 (6 issues) $32.00. Outside the U.S. and Canada add $2.70 for postage and handling.

Volume 2, 1974 (6 issues) $32.00. Price for individual subscribers certifying that the journal is for their personal use, $18.00. Outside the U.S. add $2.70 for postage and handling. Prices 10% higher outside the U.S.

Second-class postage paid at Jamaica, New York 11431.

Printed in Great Britain.

Journal of Pharmacokinetics and Biopharmaceutics is published bimonthly at Winterstoke Road, Bristol 3, England, by Plenum Publishing Corporation, 227 West 17th Street, New York, 10011. In 1973, Volume 1 (6 issues) will be published. Subscription orders should be addressed to the publisher. *Journal of Pharmacokinetics and Biopharmaceutics* is abstracted or indexed in Biological Abstracts, Chemical Abstracts, Excerpta Medica, Current Contents, and International Pharmaceutical Abstracts.

CONTENTS

Vol. 1, No. 1 **February 1973**

Introductory Statement 1

Pharmacokinetics and Biopharmaceutics: A Definition of Terms 3

Pharmacokinetics of Pentobarbital After Intravenous and Oral Adminstration 5
R. B. Smith, L. W. Dittert, W. O. Griffen, Jr., and J. T. Doluisio

Relationship Between Plasma or Serum Drug Concentration and Amount of Drug in the Body at Steady State upon Multiple Dosing 17
Donald Perrier and Milo Gibaldi

Quantitation of Rate of Gastrointestinal and Buccal Absorption of Acidic and Basic Drugs Based on Extraction Theory 23
John G. Wagner and Allen J. Sedman

Mathematical Representations of Cancer Chemotherapy Effects 51
Kenneth J. Himmelstein and Kenneth B. Bischoff

Models of ARA-C Chemotherapy of L1210 Leukemia in Mice 69
Kenneth J. Himmelstein and Kenneth B. Bischoff

SCIENTIFIC COMMENTARY

Addendum 1. Use of Isotopes in Bioavailability Testing 83
Sidney Riegelman, Malcolm Rowland, and Leslie Z. Benet

Vol. 1, No. 2 **April 1973**

Clindamycin Bioavailability from Clindamycin-2-Palmitate and Clindamycin-2-Hexadecylcarbonate in Man 89
Arlington A. Forist, Ray M. DeHaan, and Carl M. Metzler

Kinetics of Diphenylhydantoin Elimination in Rats 99
John J. Ashley and Gerhard Levy

Properties of the Michaelis–Menten Equation and Its Integrated Form Which Are Useful in Pharmacokinetics 103
John. G. Wagner

Clearance Concepts in Pharmacokinetics 123
Malcolm Rowland, Leslie Z. Benet, and Garry G. Graham

COMPT, a Time-Sharing Program for Nonlinear Regression Analysis of Compartmental Models of Drug Distribution 137
Morris Pfeffer

SCIENTIFIC COMMENTARY

Intrasubject Variation in Elimination Half-Lives of Drugs Which Are Appreciably Metabolized 165
John G. Wagner

Vol. 1, No. 3 **June 1973**

A Pharmacodynamic Model for Cell-Cycle-Specific Chemotherapeutic Agents 175
William J. Jusko

Utilization of Area Under the Curve to Elucidate the Disposition of an Extensively Biotransformed Drug 201
S. A. Kaplan, M. L. Jack, S. Cotler, and K. Alexander

Compartmental Analysis of the Effect of Carbon Tetrachloride Intoxication on Blood and Bile Kinetics of Sulfobromophthalein in Rats 217
G. Giorgi and G. Segre

Effect of Product Inhibition on Kinetics of Drug Elimination 231
Donald Perrier, John J. Ashley, and Gerhard Levy

Use of Chromatographic R_m Values as a Possible Approach to Calculation of the Absorption Rate Constants for Some Related Drugs 243
José M. Plá-Delfina, Joaquin Moreno, and Alfonso del Pozo

Pharmacokinetics of Kanamycin Following Intramuscular Administration 253
James T. Doluisio, Lewis W. Dittert, and John C. LaPiana

Vol. 1, No. 4 **August 1973**

Effect of Altered Urinary *p*H on Tetracycline and Doxycycline Excretion in Humans 267
James M. Jaffe, John L. Colaizzi, Rolland I. Poust, and Robert H. McDonald, Jr.

Bioavailability Calculations for Drugs Showing Simultaneous First-Order and Capacity-Limited Elimination Kinetics 283
Leo Martis and René H. Levy

Diazoxide Urine and Plasma Levels in Humans by Stable-Isotope Dilution–Mass Fragmentography 295
Wolfgang Sadee, Jack Segal, and Claude Finn

Preliminary Pharmacokinetic Studies of Propylthiouracil in Humans 307
D. Schuppan, S. Riegelman, B. v. Lehmann, A. Pilbrant, and C. Becker

The Oral Bioavailability and Pharmacokinetics of Soluble and Resin-Bound Forms of Amphetamine and Phentermine in Man 319
Orville N. Hinsvark, Aldo P. Truant, Donald J. Jenden, and Joseph A. Steinborn

SCIENTIFIC COMMENTARY

Drug Bioavailability and Pharmacokinetic Analysis from Pharmacological Data 329
Victor F. Smolen and William A. Weigand

Erratum: Properties of the Michaelis–Menten Equation and Its Integrated Form Which Are Useful in Pharmacokinetics 337
John G. Wagner

Vol. 1, No. 5 **October 1973**

PROCEEDINGS, IN PART, OF THE CONFERENCE ON PHARMACOLOGY AND PHARMACOKINETICS: PROBLEMS AND PERSPECTIVES, October 30–November 1, 1972, at the Fogarty International Center, National Institutes of Health, Bethesda, Maryland

Editor's Note 339

Classical Pharmacokinetics to the Frontier 341
Edward R. Garrett

A Modern View of Pharmacokinetics 363
John G. Wagner

Translation of Pharmacokinetics to Clinical Medicine 403
Lucius Dettli

Effect of Route of Administration on Drug Disposition 419
Sidney Riegelman and Malcolm Rowland

Animal Scale-Up 435
Robert L. Dedrick

Vol. 1, No. 6 **December 1973**

PROCEEDINGS, IN PART, OF THE CONFERENCE ON PHARMACOLOGY AND PHARMACOKINETICS: PROBLEMS AND PERSPECTIVES, October 30–November 1, 1972, at the Fogarty International Center, National Institutes of Health, Bethesda, Maryland

Editor's Note 463

Pharmacokinetics and Cancer Chemotherapy 465
Kenneth B. Bischoff

Pharmacokinetic Studies with Amphetamines—Relationship to Neuropsychiatric Disorders 481
Lars-M. Gunne and Erik Änggård

The Importance of Tissue Distribution in Pharmacokinetics 497
James R. Gillette

Application of Pharmacokinetic Principles to the Elucidation of Polygenically Controlled Differences in Drug Response 521
Elliot S. Vesell

Comparative Pharmacokinetics of the Anticoagulant Effect of Coumarin Drugs in Man and Rat 541
Gerhard Levy

Kinetics of Drug–Drug Interactions 553
Malcolm Rowland and Shaikh B. Matin

AUTHOR INDEX TO VOLUME 1 569

SUBJECT INDEX TO VOLUME 1 571